Drug intelligence / Profile preview

Dual-targeting CAR-NK cells (Beijing Biotech)

Development stage: Unknown
Lead developer: Beijing Biotech
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intracranial

Overview

Dual-targeting CAR-NK cells (Beijing Biotech) is an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy being developed for the treatment of recurrent or progressive glioblastoma (GBM) and other high-grade gliomas (HGG). This therapy utilizes a biomarker-guided approach where patients' tumors are profiled for the expression of three key antigens: Interleukin-13 receptor subunit alpha-2 (IL13Rα2), Epidermal growth factor receptor (EGFR, including the vIII variant), and B7-H3 (CD276). Based on the individual's antigen profile, a specific dual-targeting CAR-NK construct is selected and administered locoregionally via an intracranial catheter or reservoir. This strategy aims to overcome tumor heterogeneity and prevent antigen escape, a common cause of resistance in single-target CAR therapies. The treatment is typically preceded by lymphodepleting chemotherapy with cyclophosphamide and fludarabine.

Other names: IL13Rα2/EGFR/B7-H3 dual-targeting CAR-NK cellsDual-target chimeric antigen receptor natural killer cells

Targets

IL13RA2 (Interleukin-13 receptor subunit alpha 2)EGFRvIII (Epidermal growth factor receptor variant III)B7-H3

Beyond the preview

Go deeper on Dual-targeting CAR-NK cells (Beijing Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual-targeting CAR-NK cells (Beijing Biotech).

Explore the full profile